rs1014286 - SLC9A4
Magnitude 2.2 · 1 study on file
Reported associations
-
Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. - The Journal of clinical investigation (2013) · Ho JE, Chen WY, Chen MH, Larson MG, McCabe EL, Cheng S, Ghorbani A, Coglianese E, Emilsson V, Johnson AD, Walter S, Franceschini N, O'Donnell CJ, Dehghan A, Lu C, Levy D, Newton-Cheh C, Lin H, Felix JF, Schreiter ER, Vasan RS, Januzzi JL, Lee RT, Wang TJ · PubMed 23999434
The suppression of tumorigenicity 2/IL-33 (ST2/IL-33) pathway has been implicated in several immune and inflammatory diseases. ST2 is produced as 2 isoforms. The membrane-bound isoform (ST2L) induces an immune response when bound to its ligand, IL-33. The other isoform is a soluble protein (sST2) that is thought to be a decoy receptor for IL-33 signaling. Elevated sST2 levels in serum are associated with an increased risk for cardiovascular disease. We investigated the determinants of sST2 plasma concentrations in 2,991 Framingham Offspring Cohort participants. While clinical and environmental factors explained some variation in sST2 levels, much of the variation in sST2 production was driven by genetic factors. In a genome-wide association study (GWAS), multiple SNPs within IL1RL1 (the ge
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Bloodwork
-
sST2 (soluble ST2) levels Moderate
The G allele at rs1014286 is strongly associated with elevated serum sST2, a biomarker of cardiac stress and inflammation
Check sST2 baseline and periodically if carrying risk allele; discuss interpretation with healthcare provider
Discuss with your doctor
-
sST2 elevation and cardiovascular risk stratification Moderate
rs1014286 G allele carriers have higher sST2 levels, which associates with cardiac stress, heart failure risk, and inflammatory state
Review sST2 results in context of other cardiovascular risk factors and discuss management approach